Mentari Therapeutics(MTRI)
$18.35+2.74 (+17.56%)
MTRI
Mentari Therapeutics stock kpis
$18.35
At close:+2.74 (+17.56%)
Want to see MTRI full AI Analyst Report?
Net Income By Segment
Reveals profitability across different segments, indicating which areas are driving earnings and which might be underperforming or facing challenges.
InMed Pharmaceuticals shows a fluctuating net income trend with recent improvements, particularly in the BayMedica segment, which turned positive in mid-2023 and maintained profitability into 2025. This suggests successful operational adjustments or market strategies. However, the InMed segment continues to face challenges with persistent losses, indicating a need for strategic interventions to stabilize and potentially leverage BayMedica's positive momentum for overall financial health.
MTRI Net Income By Segment
| Date | InMed | BayMedica |
|---|---|---|
| Jun 30, 2026 | C$0.00 | -C$996.33K |
| Mar 31, 2026 | C$0.00 | -C$174.59K |
| Dec 31, 2025 | -C$1.91M | -C$120.24K |
| Sep 30, 2025 | -C$1.83M | C$103.45K |
| Jun 30, 2025 | -C$1.83M | C$46.30K |
| Mar 31, 2025 | -C$2.07M | -C$53.86K |
| Dec 31, 2024 | -C$2.81M | C$234.97K |
| Sep 30, 2024 | -C$1.98M | C$300.76K |
| Jun 30, 2024 | -C$3.22M | C$1.29M |
| Mar 31, 2024 | -C$1.79M | C$68.72K |
| Dec 31, 2023 | -C$1.07M | -C$410.17K |
| Sep 30, 2023 | -C$1.78M | -C$753.08K |
| Jun 30, 2023 | -C$1.25M | C$907.53K |
| Mar 31, 2023 | -C$1.61M | -C$391.03K |
| Dec 31, 2022 | -C$1.61M | -C$487.51K |
| Sep 30, 2022 | -C$2.27M | -C$1.24M |
| Jun 30, 2022 | -C$3.93M | -C$3.94M |
| Mar 31, 2022 | -C$2.94M | -C$534.71K |
| Dec 31, 2021 | -C$3.56M | -C$717.95K |
| Sep 30, 2021 | -C$2.97M | C$0.00 |
